H. Lundbeck Adds North American Rights To Desmoteplase In Revised Deal With Paion
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish firm plans a new Phase III trial for the second half of 2008 based on reanalysis of data from failed studies of the clot-busting agent.